Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial

Abstract To examine long-term effects of early intervention services (EIS) for first-episode psychosis, we compared Heinrichs-Carpenter Quality of Life (QLS) and Positive and Negative Syndrome Scale (PANSS) scores and inpatient hospitalization days over 5 years with data from the site-randomized RAI...

Full description

Saved in:
Bibliographic Details
Published in:Schizophrenia bulletin 2022-09, Vol.48 (5), p.1021-1031
Main Authors: Robinson, Delbert G, Schooler, Nina R, Marcy, Patricia, Gibbons, Robert D, Hendricks Brown, C, John, Majnu, Mueser, Kim T, Penn, David L, Rosenheck, Robert A, Addington, Jean, Brunette, Mary F, Correll, Christoph U, Estroff, Sue E, Mayer-Kalos, Piper S, Gottlieb, Jennifer D, Glynn, Shirley M, Lynde, David W, Gingerich, Susan, Pipes, Ronny, Miller, Alexander L, Severe, Joanne B, Kane, John M
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antipsychotic Agents - therapeutic use
Diagnostic and Statistical Manual of Mental Disorders
Humans
Psychotic Disorders - diagnosis
Quality of Life
Regular
Schizophrenia - drug therapy
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To examine long-term effects of early intervention services (EIS) for first-episode psychosis, we compared Heinrichs-Carpenter Quality of Life (QLS) and Positive and Negative Syndrome Scale (PANSS) scores and inpatient hospitalization days over 5 years with data from the site-randomized RAISE-ETP trial that compared the EIS NAVIGATE (17 sites; 223 participants) and community care (CC) (17 sites; 181 participants). Inclusion criteria were: age 15–40 years; DSM-IV diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified; first psychotic episode; antipsychotic medication taken for ≤6 months. NAVIGATE-randomized participants could receive NAVIGATE from their study entry date until NAVIGATE ended when the last-enrolled NAVIGATE participant completed 2 years of treatment. Assessments occurred every 6 months. 61% of participants had assessments conducted ≥2 years; 31% at 5 years. Median follow-up length was CC 30 months and NAVIGATE 38 months. Primary analyses assumed data were not-missing-at-random (NMAR); sensitivity analyses assumed data were missing-at-random (MAR). MAR analyses found no significant treatment-by-time interactions for QLS or PANSS. NMAR analyses revealed that NAVIGATE was associated with a 13.14 (95%CI:6.92,19.37) unit QLS and 7.73 (95%CI:2.98,12.47) unit PANSS better improvement and 2.53 (95%CI:0.59,4.47) fewer inpatient days than CC (all comparisons significant). QLS and PANSS effect sizes were 0.856 and 0.70. NAVIGATE opportunity length (mean 33.8 (SD = 5.1) months) was not associated (P = .72) with QLS outcome; duration of untreated psychosis did not moderate (P = .32) differential QLS outcome. While conclusions are limited by the low rate of five-year follow-up, the data support long-term benefit of NAVIGATE compared to community care.
ISSN:0586-7614
1745-1701
DOI:10.1093/schbul/sbac053